{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:55:12Z","timestamp":1790996112333,"version":"4.1.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Poly (ADP-ribose) polymerase (PARP) enzymes are critical in repairing DNA damage induced by chemotherapy and\/or radiation. Due to PARP\u2019s role in DNA repair, inhibiting PARP leads to genomic instability and accumulation of damaged cells in cell cycle arrest. Previous studies have shown that PARP1 activation contributes to the development of various malignant disorders, and using PARP inhibitors is a promising intervention in these diseases. However, PARP activation is also common in neurological and inflammatory disorders. PARP inhibitors were studied in preclinical models of neurodegenerative disorders such as Parkinson\u2019s, Huntington\u2019s, and Alzheimer\u2019s Disease (AD). In neurodegenerative disorders like AD, activated PARP1 induces A\u03b2 and forms Tau tangles, worsening cognitive symptoms. PARP inhibitors are currently used in combination therapy with chemotherapy drugs, including cisplatin and temozolomide, which are all described as having significant rates of central and peripheral nervous system side-effects, raising the potential question of using PARP inhibition not only as a cancer treatment but as an approach to mitigate the toxicity of the cancer drugs. This review will summarize evidence for the potential use of PARP inhibitors for neurologic disorders and discuss future prospects of how PARP inhibitors could be repurposed as neuroprotective agents against the cognitive complications of chemotherapeutic drugs.<\/jats:p>","DOI":"10.3389\/fphar.2025.1615843","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T05:24:18Z","timestamp":1749446658000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["The role of Poly-ADP ribose polymerase (PARP) enzymes in chemotherapy-induced cognitive impairments \u2013 parallels with other neurodegenerative disorders"],"prefix":"10.3389","volume":"16","author":[{"given":"Dahlia A.","family":"Ordaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpna","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela A.","family":"Bota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.pbb.2020.172859","article-title":"5-aminoisoquinolinone attenuates social behavior deficits and immune abnormalities in the BTBR T+ Itpr3tf\/J mouse model for autism","author":"Ahmad","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/s0197-4580(00)00124-x","article-title":"Inflammation and Alzheimer's disease","volume":"21","author":"Akiyama","year":"2000","journal-title":"Neurobiol. Aging"},{"key":"B3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-e","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group","volume":"72","author":"Author anonymous","year":"1993","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/s0140-6736(21)00218-x","article-title":"Parkinson's disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1073\/pnas.1016574108","article-title":"Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression","volume":"108","author":"Boehler","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B6","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant p53 in cancer: from molecular mechanism to therapeutic modulation","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death & Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1002\/1878-0261.13285","article-title":"DNA repair as a shared hallmark in cancer and ageing","volume":"16","author":"Clarke","year":"2022","journal-title":"Mol. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e55375","DOI":"10.1371\/journal.pone.0055375","article-title":"Triggering of inflammasome by aggregated \u03b1\u2013synuclein, an inflammatory response in synucleinopathies","volume":"8","author":"Codolo","year":"2013","journal-title":"PLOS ONE"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1016\/j.molcel.2021.05.009","article-title":"XRCC1 prevents toxic PARP1 trapping during DNA base excision repair","volume":"81","author":"Demin","year":"2021","journal-title":"Mol. Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"zcad009","DOI":"10.1093\/narcan\/zcad009","article-title":"Mono-ADP-ribosylation by PARP10 and PARP14 in genome stability","volume":"5","author":"Dhoonmoon","year":"2023","journal-title":"Nar. Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain - PubMed","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20141337","article-title":"Analysis of the intricate relationship between chronic inflammation and cancer - PubMed","volume":"468","author":"Ez","year":"2015","journal-title":"Biochem. J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fnbeh.2016.00121","article-title":"Dopamine replacement therapy, learning and reward prediction in Parkinson\u2019s disease: implications for rehabilitation","volume":"10","author":"Ferrazzoli","year":"2016","journal-title":"Front. Behav. Neurosci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death & Differ."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1062993","DOI":"10.3389\/fcell.2022.1062993","article-title":"Mitochondria inter-organelle relationships in cancer protein aggregation","volume":"10","author":"Genovese","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.3390\/cancers14061420","article-title":"PARP inhibitors resistance: mechanisms and perspectives","volume":"14","author":"Giudice","year":"2022","journal-title":"Cancers"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmr.2024.100030","article-title":"Cell cycle dysregulation in cancer - PubMed","volume":"77","author":"Glaviano","year":"2024","journal-title":"Pharmacol. Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"S611-S631","DOI":"10.3233\/JAD-179935","article-title":"Role of amyloid-\u03b2 and tau proteins in Alzheimer\u2019s disease: confuting the amyloid cascade","volume":"64","author":"Gulisano","year":"2018","journal-title":"J. Alzheimer's Dis. JAD"},{"key":"B19","doi-asserted-by":"publisher","first-page":"104492","DOI":"10.1016\/j.neuint.2019.104492","article-title":"Enhancement of ATP production ameliorates motor and cognitive impairments in a mouse model of MPTP\u2212induced Parkinson's disease","volume":"129","author":"Haga","year":"2019","journal-title":"Neurochem. Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.freeradbiomed.2017.04.018","article-title":"PARP inhibition protects mitochondria and reduces ROS production via PARP-1-ATF4-MKP-1-MAPK retrograde pathway","volume":"108","author":"Hocsak","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"102078","DOI":"10.1016\/j.arr.2023.102078","article-title":"Poly (ADP-ribose) polymerase 1 and neurodegenerative diseases: past, present, and future","volume":"91","author":"Hu","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"18512","DOI":"10.1038\/srep18512","article-title":"PARP6 is a regulator of hippocampal dendritic morphogenesis","volume":"6","author":"Huang","year":"2016","journal-title":"Sci. Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/JCO.2015.64.3205","article-title":"Longitudinal assessment of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia treated on a contemporary chemotherapy protocol","volume":"34","author":"Jacola","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.769184","article-title":"Frontiers | molecular strategies to target protein aggregation in Huntington\u2019s disease","volume":"8","author":"Jarosi\u0144ska","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"eaat8407","DOI":"10.1126\/science.aat8407","article-title":"Poly (ADP-ribose) drives pathologic \u03b1-synuclein neurodegeneration in Parkinson\u2019s disease","volume":"362","author":"Kam","year":"2018","journal-title":"Sci. (New York, N.Y.)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"105028","DOI":"10.1016\/j.nbd.2020.105028","article-title":"Microglia and astrocyte dysfunction in Parkinson\u2019s disease","volume":"144","author":"Kam","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30938-0","article-title":"Pharmacologic management of cognitive impairment induced by cancer therapy","volume":"20","author":"Karschnia","year":"2019","journal-title":"Lancet. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3390\/cells8091047","article-title":"The role of PARPs in inflammation\u2014and metabolic\u2014related diseases: molecular mechanisms and beyond","volume":"8","author":"Ke","year":"2019","journal-title":"Cells"},{"key":"B29","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/s41598-018-37164-8","article-title":"Exposure to environmental radionuclides associates with tissue-specific impacts on telomerase expression and telomere length","volume":"9","author":"Kes\u00e4niemi","year":"2019","journal-title":"Sci. Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"113637","DOI":"10.1016\/j.biopha.2022.113637","article-title":"Inhibition of \u03b1-synuclein aggregation by MT101-5 is neuroprotective in mouse models of Parkinson\u2019s disease","volume":"154","author":"Kim","year":"2022","journal-title":"Biomed. & Pharmacother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3233\/JHD-160205","article-title":"Oxidative stress and Huntington\u2019s disease: the good, the bad, and the ugly","volume":"5","author":"Kumar","year":"2016","journal-title":"J. Huntingt. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bbrc.2023.02.075","article-title":"Therapeutic targeting of Huntington's disease: molecular and clinical approaches","volume":"655","author":"Kumar","year":"2023","journal-title":"Biochem. Biophysical Res. Commun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s11523-021-00841-2","article-title":"Niraparib: a review in first-line maintenance therapy in advanced ovarian cancer","volume":"16","author":"Lee","year":"2021","journal-title":"Target. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The warburg effect: how does it benefit cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"7497","DOI":"10.1093\/nar\/gkm821","article-title":"Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease","volume":"35","author":"Lovell","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.3390\/cells11081284","article-title":"Neuroprotective effects of PARP inhibitors in Drosophila models of Alzheimer\u2019s disease","volume":"11","author":"Maggiore","year":"2022","journal-title":"Cells"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1111\/febs.15716","article-title":"The role of PARP1 in neurodegenerative diseases and aging","volume":"289","author":"Mao","year":"2022","journal-title":"FEBS J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s42003-023-04596-6","article-title":"PARP1 allows proper telomere replication through TRF1 poly (ADP-ribosyl)ation and helicase recruitment","volume":"6","author":"Maresca","year":"2023","journal-title":"Commun. Biol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington's disease: a clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur. J. Neurology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.phrs.2018.09.031","article-title":"PARP inhibition in platinum-based chemotherapy: chemopotentiation and neuroprotection","volume":"137","author":"McQuade","year":"2018","journal-title":"Pharmacol. Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.nbd.2016.08.015","article-title":"Symptom heterogeneity in Huntington's disease correlates with neuronal degeneration in the cerebral cortex","volume":"96","author":"Mehrabi","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/nejmoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3233\/ADR-210061","article-title":"Neuroprotective effects of cholinesterase inhibitors: current scenario in therapies for Alzheimer\u2019s disease and future perspectives","volume":"6","author":"Moreira","year":"2022","journal-title":"J. Alzheimer's Dis. Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1091\/mbc.E18-10-0650","article-title":"NAD+ consumption by PARP1 in response to DNA damage triggers metabolic shift critical for damaged cell survival","volume":"30","author":"Murata","year":"2019","journal-title":"Mol. Biol. Cell"},{"key":"B45","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s11060-016-2188-8","article-title":"The effects of sequential treatments on hippocampal volumes in malignant glioma patients","volume":"129","author":"Nolen","year":"2016","journal-title":"J. neuro-oncology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.bbrc.2007.03.163","article-title":"Pharmacological inhibition of PARP-1 reduces \u03b1-synuclein- and MPP+-induced cytotoxicity in Parkinson\u2019s disease in vitro models","volume":"357","author":"Outeiro","year":"2007","journal-title":"Biochem. Biophysical Res. Commun."},{"key":"B47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/cells9010041","article-title":"Multifaceted role of PARP-1 in DNA repair and inflammation: pathological and therapeutic implications in cancer and non-cancer diseases","volume":"9","author":"Pazzaglia","year":"2019","journal-title":"Cells"},{"key":"B48","doi-asserted-by":"publisher","first-page":"10\/13","DOI":"10.3390\/biom11101508","article-title":"Mitochondrial dysfunction, protein misfolding and neuroinflammation in Parkinson's disease: roads to biomarker discovery - PubMed","volume":"11","author":"Picca","year":"2021","journal-title":"Biomolecules"},{"key":"B49","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.cortex.2022.03.009","article-title":"Regional changes of brain structure during progression of idiopathic Parkinson's disease \u2013 a longitudinal study using deformation based morphometry","volume":"151","author":"Pieperhoff","year":"2022","journal-title":"Cortex"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0312-6","article-title":"Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts - PubMed","volume":"119","author":"P\u00f3ti","year":"2018","journal-title":"Br. J. cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3233\/JAD-160612","article-title":"Amyloid beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer\u2019s disease neurons","volume":"57","author":"Rajmohan","year":"2017","journal-title":"J. Alzheimer's Dis. JAD"},{"key":"B53","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3389\/fnagi.2020.00255","article-title":"Nicotinamide, a poly [ADP-Ribose] polymerase 1 (PARP-1) inhibitor, as an adjunctive therapy for the treatment of Alzheimer\u2019s disease","volume":"12","author":"Salech","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.3390\/cancers13164198","article-title":"Neuroinflammation and its association with cognition, neuronal markers and peripheral inflammation after chemotherapy for breast cancer","volume":"13","author":"Schroyen","year":"2021","journal-title":"Cancers"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.3390\/biom13101480","article-title":"Combination treatment strategies to overcome PARP inhibitor resistance","volume":"13","author":"Soung","year":"2023","journal-title":"Biomolecules"},{"key":"B56","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pbb.2015.03.022","article-title":"Poly (ADP-ribose) polymerase-1 inhibitor, 3-aminobenzamide pretreatment ameliorates lipopolysaccharide-induced neurobehavioral and neurochemical anomalies in mice","volume":"133","author":"Sriram","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B57","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0168-9525(03)00074-X","article-title":"Transcriptional abnormalities in Huntington disease","volume":"19","author":"Sugars","year":"2003","journal-title":"Trends Genet."},{"key":"B58","doi-asserted-by":"publisher","first-page":"851246","DOI":"10.3389\/fphar.2022.851246","article-title":"Adverse event profiles of PARP inhibitors: Analysis of spontaneous reports submitted to FAERS","volume":"13","author":"Tian","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s12609-010-0026-0","article-title":"PARP inhibitors for the treatment and prevention of breast cancer","volume":"2","author":"Vinayak","year":"2010","journal-title":"Curr. breast cancer Rep."},{"key":"B60","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00401-004-0957-5","article-title":"Expression pattern of apoptosis-related markers in Huntington\u2019s disease","volume":"109","author":"Vis","year":"2005","journal-title":"Acta Neuropathol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"6313","DOI":"10.3390\/ijms24076313","article-title":"DNA damage-mediated neurotoxicity in Parkinson\u2019s disease","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"26642","DOI":"10.1074\/jbc.M114.589515","article-title":"PARP12, an interferon-stimulated gene involved in the control of protein translation and inflammation","volume":"289","author":"Welsby","year":"2014","journal-title":"J. Biol. Chem."},{"key":"B63","doi-asserted-by":"publisher","first-page":"111694","DOI":"10.1016\/j.pscychresns.2023.111694","article-title":"Hippocampal morphology in Huntington's disease, implications for plasticity and pathogenesis: the IMAGE-HD study","volume":"335","author":"Wilkes","year":"2023","journal-title":"Psychiatry Res. Neuroimaging"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/5288698","article-title":"Dietary plant polyphenols as the potential drugs in neurodegenerative diseases: current evidence, advances, and opportunities","volume":"2022","author":"Yan","year":"2022","journal-title":"Oxidative Med. Cell. Longev."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00018-016-2202-5","article-title":"Regulation of necrotic cell death: p53, PARP1 and cyclophilin D-overlapping pathways of regulated necrosis?","volume":"73","author":"Ying","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41598-018-36538-2","article-title":"Partial depletion of dopaminergic neurons in the substantia nigra impairs olfaction and alters neural activity in the olfactory bulb","volume":"9","author":"Zhang","year":"2019","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1615843\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T05:24:19Z","timestamp":1749446659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1615843\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":66,"alternative-id":["10.3389\/fphar.2025.1615843"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1615843","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"article-number":"1615843"}}